| Lenvatinib studied in …STUDIED_INderived200 of 388show all (up to 200) |
|---|
| → studied in | NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · 388 trials list this drug (172 active) | — | — | Esophageal Neoplasm,Gastric Neoplasm,Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06110793Phase 1/Phase 2 · active not recruiting A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer · 388 trials list this drug (172 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07843901Phase 2 · not yet recruiting Lenvatinib in Patients With Advanced Parathyroid Carcinoma · 388 trials list this drug (172 active) | — | — | Parathyroid Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04626479Phase 1/Phase 2 · completed Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04626518Phase 1/Phase 2 · completed Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05188118early Phase 1 · completed Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07594015Phase 2 · recruiting Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance · 388 trials list this drug (172 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07219459Phase 2 · recruiting Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07405164Phase 3 · recruiting Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · 388 trials list this drug (172 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07835893Phase 2 · recruiting Lenvatinib Plus Chemotherapy for pNET Liver Metastases · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07836530Phase 3 · not yet recruiting Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma,Malignant Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06858813Phase 1 · recruiting A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) · 388 trials list this drug (172 active) | — | — | Liver Neoplasm,Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07829874Phase 2 · not yet recruiting Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer. · 388 trials list this drug (172 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07829926Phase 2 · not yet recruiting Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07832006Phase 2 · recruiting Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03950609Phase 2 · active not recruiting Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors · 388 trials list this drug (172 active) | — | — | Digestive System Neuroendocrine Neoplasm,Neuroendocrine Neoplasm,Multiple Endocrine Neoplasia Type 1+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05327686Phase 2 · recruiting Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07827807Phase 2 · not yet recruiting PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03486873Phase 3 · recruiting Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) · 388 trials list this drug (172 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06462183Phase 1 · active not recruiting Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC) · 388 trials list this drug (172 active) | — | — | Adenoid Cystic Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06318286Phase 2 · active not recruiting Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma · 388 trials list this drug (172 active) | — | — | Pleural Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07776080Phase 2 · recruiting Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04977453Phase 1/Phase 2 · recruiting GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors · 388 trials list this drug (172 active) | — | — | Solid Neoplasm,Urothelial Carcinoma,Clear Cell Renal Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05012371Phase 2 · active not recruiting Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer · 388 trials list this drug (172 active) | — | — | Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04865887Phase 2 · recruiting Pembrolizumab and Lenvatinib in Advanced Cervical Cancer · 388 trials list this drug (172 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05877820Phase 2 · completed A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC · 388 trials list this drug (172 active) | — | — | Fumarate Hydratase-Deficient Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05774899Phase 1/Phase 2 · recruiting CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC · 388 trials list this drug (172 active) | — | — | Adenoid Cystic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04246177Phase 3 · terminated Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05319730Phase 1/Phase 2 · recruiting A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) · 388 trials list this drug (172 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04305041Phase 1/Phase 2 · completed Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) · 388 trials list this drug (172 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04427293Phase 1 · active not recruiting Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) · 388 trials list this drug (172 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06682780Phase 1/Phase 2 · recruiting A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours · 388 trials list this drug (172 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05789667completed Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06187961Phase 2 · recruiting HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04039607Phase 3 · completed A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04770896Phase 3 · active not recruiting A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05775159Phase 2 · active not recruiting Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma,Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04949256Phase 3 · terminated Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). · 388 trials list this drug (172 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05899049Phase 3 · active not recruiting A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04736706Phase 3 · active not recruiting A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04924101Phase 2 · completed Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) · 388 trials list this drug (172 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05733715early Phase 1 · recruiting Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05308901Phase 2 · terminated Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma · 388 trials list this drug (172 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04887805Phase 2 · active not recruiting Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer · 388 trials list this drug (172 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06880523Phase 2 · recruiting STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04171622Phase 2 · active not recruiting Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer · 388 trials list this drug (172 active) | — | — | Thyroid Gland Anaplastic Carcinoma,Thyroid Gland Anaplastic Carcinoma, Squamous Cell Carcinoma Pattern,Thyroid Gland Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05114421Phase 2 · active not recruiting Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients · 388 trials list this drug (172 active) | — | — | Fallopian Tube High Grade Serous Adenocarcinoma,Ovarian High Grade Serous Adenocarcinoma,Primary Peritoneal High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07754734Phase 2 · not yet recruiting STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation · 388 trials list this drug (172 active) | — | — | Glioblastoma,Glioma,MGMT-Methylated Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07475026Phase 3 · recruiting A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05168163Phase 2 · recruiting Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05603910Phase 1 · recruiting Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma · 388 trials list this drug (172 active) | — | — | Endometrial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05081180Phase 1 · terminated Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors · 388 trials list this drug (172 active) | — | — | Central Nervous System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05258279Phase 2 · completed Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations · 388 trials list this drug (172 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05621499NA · active not recruiting HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07715565Phase 2 · not yet recruiting Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05041153early Phase 1 · active not recruiting Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma · 388 trials list this drug (172 active) | — | — | Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05273554Phase 1 · active not recruiting A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma · 388 trials list this drug (172 active) | — | — | Neoplasm,Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07686926Phase 2 · not yet recruiting Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II · 388 trials list this drug (172 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07704177Phase 2 · recruiting Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07691515Phase 3 · not yet recruiting Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma · 388 trials list this drug (172 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02861573Phase 1/Phase 2 · active not recruiting Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) · 388 trials list this drug (172 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05301842Phase 3 · active not recruiting Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07685535Phase 2 · not yet recruiting HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma · 388 trials list this drug (172 active) | — | — | Malignant Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07680088Phase 2 · not yet recruiting Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer · 388 trials list this drug (172 active) | — | — | Anal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04740307Phase 2 · completed Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07670273Phase 2 · recruiting Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04321954Phase 2 · completed Lenvatinib in Locally Advanced Invasive Thyroid Cancer · 388 trials list this drug (172 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04929392Phase 2 · active not recruiting Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer · 388 trials list this drug (172 active) | — | — | Esophageal Squamous Cell Carcinoma,Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07383441Phase 3 · recruiting Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · 388 trials list this drug (172 active) | — | — | Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06986785Phase 2 · recruiting A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07466225active not recruiting HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03516981Phase 2 · completed A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) · 388 trials list this drug (172 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04300556Phase 1/Phase 2 · recruiting A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types · 388 trials list this drug (172 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04955743Phase 2 · terminated Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma · 388 trials list this drug (172 active) | — | — | Melanoma,Brain Neoplasm,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02780310Phase 2 · active not recruiting Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma · 388 trials list this drug (172 active) | — | — | Adenoid Cystic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04164199Phase 3 · completed Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04938817Phase 1/Phase 2 · active not recruiting Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98) · 388 trials list this drug (172 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04305054Phase 1/Phase 2 · completed Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) · 388 trials list this drug (172 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07495579Phase 2 · not yet recruiting Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05585580Phase 2 · active not recruiting Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07493668Phase 2 · recruiting Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04848337Phase 2 · active not recruiting Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer · 388 trials list this drug (172 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05903833Phase 2 · recruiting Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy · 388 trials list this drug (172 active) | — | — | Vulvar Neoplasm,Malignant Vulvar Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07571551Phase 2 · recruiting Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma · 388 trials list this drug (172 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06266338Phase 2 · recruiting Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix) · 388 trials list this drug (172 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04199104Phase 3 · completed A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) · 388 trials list this drug (172 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04586231Phase 3 · active not recruiting A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07014150Phase 2 · recruiting Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03797326Phase 2 · completed Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) · 388 trials list this drug (172 active) | — | — | Solid Neoplasm,Glioblastoma,Malignant Gastric Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05384015Phase 2 · active not recruiting Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer · 388 trials list this drug (172 active) | — | — | Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05103904Phase 2 · terminated Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04207086Phase 2 · active not recruiting A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma · 388 trials list this drug (172 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04784247Phase 2 · active not recruiting Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma · 388 trials list this drug (172 active) | — | — | Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07328009Phase 2 · recruiting A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04393350Phase 2 · active not recruiting Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma · 388 trials list this drug (172 active) | — | — | Malignant Kidney Neoplasm,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07537946Phase 3 · not yet recruiting Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07537985NA · completed Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05064280Phase 2 · recruiting Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases · 388 trials list this drug (172 active) | — | — | Neoplasm,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06669572Phase 2 · recruiting Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment · 388 trials list this drug (172 active) | — | — | Squamous Cell Carcinoma,Malignant Anorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04745988Phase 2 · active not recruiting An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer · 388 trials list this drug (172 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05696548Phase 2 · active not recruiting Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION) · 388 trials list this drug (172 active) | — | — | Thyroid Gland Anaplastic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06253494Phase 1/Phase 2 · recruiting Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer · 388 trials list this drug (172 active) | — | — | Endometrial Carcinoma,Endometrial Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07518706Phase 2 · not yet recruiting Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07096609Phase 1/Phase 2 · recruiting Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients · 388 trials list this drug (172 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07290894Phase 2 · recruiting Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01 · 388 trials list this drug (172 active) | — | — | Vulvar Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07487662Phase 2 · not yet recruiting TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04008797Phase 1/Phase 2 · active not recruiting A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor · 388 trials list this drug (172 active) | — | — | Neoplasm,Liver Neoplasm,Colorectal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03517449Phase 3 · completed Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) · 388 trials list this drug (172 active) | — | — | Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06036836Phase 2 · completed Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) · 388 trials list this drug (172 active) | — | — | Solid Neoplasm,Skin Squamous Cell Carcinoma,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05746208Phase 2 · recruiting Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors · 388 trials list this drug (172 active) | — | — | Neuroendocrine Carcinoma,Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07092514Phase 2 · recruiting Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC) · 388 trials list this drug (172 active) | — | — | Malignant Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05523323Phase 3 · completed A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension · 388 trials list this drug (172 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05824468Phase 2 · active not recruiting Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer · 388 trials list this drug (172 active) | — | — | Cervical Carcinoma,Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05824481Phase 2 · active not recruiting Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer · 388 trials list this drug (172 active) | — | — | Endometrial Adenocarcinoma,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07460206Phase 2 · not yet recruiting Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment · 388 trials list this drug (172 active) | — | — | Clear Cell Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06859684Phase 2 · recruiting Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial) · 388 trials list this drug (172 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03573960Phase 4 · completed A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer · 388 trials list this drug (172 active) | — | — | Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06114940Phase 2 · terminated Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PLUTO) · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07432568Phase 2 · not yet recruiting A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC · 388 trials list this drug (172 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02811861Phase 3 · active not recruiting Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03829332Phase 3 · completed Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) · 388 trials list this drug (172 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04710628Phase 2 · completed Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents · 388 trials list this drug (172 active) | — | — | Thymus Carcinoma,Thymoma Type B3 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07412054Phase 2 · not yet recruiting Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07408804NA · recruiting Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04781088Phase 2 · active not recruiting Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · 388 trials list this drug (172 active) | — | — | Primary Peritoneal Carcinoma,Ovarian Carcinoma,Platinum-Resistant Primary Peritoneal Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03820986Phase 3 · completed Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) · 388 trials list this drug (172 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03713593Phase 3 · completed Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03829319Phase 3 · completed Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03898180Phase 3 · completed Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) · 388 trials list this drug (172 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04776148Phase 3 · completed Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) · 388 trials list this drug (172 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03884101Phase 3 · completed Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) · 388 trials list this drug (172 active) | — | — | Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05166239Phase 2 · completed HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04550624Phase 2 · completed Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma · 388 trials list this drug (172 active) | — | — | Biliary Tract Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05155189Phase 1 · recruiting A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03313206Phase 2 · active not recruiting Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07340502not yet recruiting TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07297654Phase 2 · not yet recruiting First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04889118Phase 3 · completed Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study · 388 trials list this drug (172 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03290079Phase 2 · completed Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors · 388 trials list this drug (172 active) | — | — | Neuroendocrine Carcinoma,Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05030506Phase 1 · active not recruiting A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05342636Phase 1/Phase 2 · completed A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A) · 388 trials list this drug (172 active) | — | — | Esophageal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05296512Phase 2 · active not recruiting Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer · 388 trials list this drug (172 active) | — | — | Malignant Female Reproductive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07282262Phase 2 · recruiting An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy. · 388 trials list this drug (172 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07282509Phase 1/Phase 2 · not yet recruiting Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05077215Phase 3 · not yet recruiting Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer · 388 trials list this drug (172 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05106127Phase 2 · not yet recruiting Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem · 388 trials list this drug (172 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03526679Phase 1/Phase 2 · completed Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma · 388 trials list this drug (172 active) | — | — | Malignant Neoplasm,Liposarcoma,Soft Tissue Sarcoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04428151Phase 2 · completed Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) · 388 trials list this drug (172 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04704219Phase 2 · completed Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04865289Phase 3 · completed Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study · 388 trials list this drug (172 active) | — | — | Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05433116Phase 2 · active not recruiting Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC · 388 trials list this drug (172 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07157969Phase 2 · recruiting ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07149090Phase 1/Phase 2 · recruiting Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites · 388 trials list this drug (172 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06962787Phase 2 · recruiting A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer · 388 trials list this drug (172 active) | — | — | Kidney Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04700072Phase 1/Phase 2 · completed Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) · 388 trials list this drug (172 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05091346Phase 1/Phase 2 · completed A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors · 388 trials list this drug (172 active) | — | — | Melanoma,Colorectal Neoplasm,Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05033522Phase 2/Phase 3 · suspended Immunotherapy for Advanced Liver Cancer · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03564691Phase 1 · completed Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) · 388 trials list this drug (172 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04209660Phase 2 · active not recruiting Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers · 388 trials list this drug (172 active) | — | — | Adenoid Cystic Carcinoma,Malignant Salivary Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04447755Phase 2 · completed A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05263492Phase 2 · terminated Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer · 388 trials list this drug (172 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06030037Phase 2 · withdrawn Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07177716Phase 2/Phase 3 · not yet recruiting Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer · 388 trials list this drug (172 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04716933Phase 3 · completed Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07159217Phase 2 · not yet recruiting Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer · 388 trials list this drug (172 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02973997Phase 2 · completed Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) · 388 trials list this drug (172 active) | — | — | Thyroid Gland Follicular Carcinoma,Thyroid Gland Oncocytic Carcinoma,Differentiated Thyroid Gland Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05014828Phase 2 · completed To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors · 388 trials list this drug (172 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07131501Phase 2 · not yet recruiting A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03976375Phase 3 · completed Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) · 388 trials list this drug (172 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05822752Phase 2 · active not recruiting Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06740370NA · recruiting TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07011849Phase 2 · withdrawn Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases · 388 trials list this drug (172 active) | — | — | Brain Neoplasm,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07070700Phase 2 · recruiting Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma · 388 trials list this drug (172 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05078931Phase 2 · active not recruiting A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients · 388 trials list this drug (172 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04522323Phase 1 · active not recruiting A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04729348Phase 2 · terminated Pembrolizumab And Lenvatinib In Leptomeningeal Metastases · 388 trials list this drug (172 active) | — | — | Solid Neoplasm,Adult Solid Neoplasm,Meningeal Carcinomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02678780Phase 2 · completed Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors · 388 trials list this drug (172 active) | — | — | Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05101629Phase 2 · completed Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07077798NA · not yet recruiting Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06161558Phase 1 · withdrawn Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors · 388 trials list this drug (172 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05797805Phase 1/Phase 2 · recruiting A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07047586Phase 2 · recruiting Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07010393Phase 4 · not yet recruiting Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study · 388 trials list this drug (172 active) | — | — | Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02720068Phase 1 · completed Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) · 388 trials list this drug (172 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06984718Phase 2 · not yet recruiting A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06420440Phase 2 · recruiting Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06904196Phase 2 · recruiting Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03324373Phase 1 · completed Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05342194Phase 3 · recruiting Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study · 388 trials list this drug (172 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03609359Phase 2 · completed Lenvatinib and Pembrolizumab Simultaneous Combination Study · 388 trials list this drug (172 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06919848Phase 2 · not yet recruiting Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06) · 388 trials list this drug (172 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05901194Phase 1/Phase 2 · active not recruiting Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04976634Phase 2 · active not recruiting Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) · 388 trials list this drug (172 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06860477Phase 2 · recruiting Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01) · 388 trials list this drug (172 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04676412Phase 3 · completed Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study · 388 trials list this drug (172 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03173560Phase 2 · completed Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06904014Phase 2 · recruiting Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05713994recruiting Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma · 388 trials list this drug (172 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03899428Phase 2 · recruiting Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC · 388 trials list this drug (172 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04267120Phase 2 · terminated Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) · 388 trials list this drug (172 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |